Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.589
-0.035 (-5.58%)
At close: Apr 28, 2026, 4:00 PM EDT
0.580
-0.009 (-1.54%)
Pre-market: Apr 29, 2026, 8:54 AM EDT

Galmed Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-10.31-7.52-6.91-17.87-32.47
Upgrade
Depreciation & Amortization
-0.080.030.040.04
Upgrade
Loss (Gain) From Sale of Investments
2.561.140.030.520.08
Upgrade
Stock-Based Compensation
0.550.530.891.31.89
Upgrade
Other Operating Activities
-0.020.61-0.31-0.040.01
Upgrade
Change in Accounts Receivable
0.24-0.190.350.3-0.31
Upgrade
Change in Accounts Payable
0.7-0.57-0.68-2.31-2.18
Upgrade
Change in Other Net Operating Assets
-0.020.040.47-0.440.04
Upgrade
Operating Cash Flow
-6.32-5.88-6.14-18.5-32.89
Upgrade
Capital Expenditures
----0-0.01
Upgrade
Investment in Securities
-3.38-0.860.817.5711.47
Upgrade
Other Investing Activities
--0.25---0
Upgrade
Investing Cash Flow
-3.38-1.110.817.5611.46
Upgrade
Issuance of Common Stock
9.038.796.190.0717.37
Upgrade
Financing Cash Flow
9.038.796.190.0717.37
Upgrade
Net Cash Flow
-0.661.80.85-0.87-4.06
Upgrade
Free Cash Flow
-6.32-5.88-6.14-18.51-32.9
Upgrade
Free Cash Flow Per Share
-1.47-6.32-26.59-132.48-240.78
Upgrade
Levered Free Cash Flow
-3.83-4.42-3.63-12.16-21.08
Upgrade
Unlevered Free Cash Flow
-3.78-4.04-3.63-12.16-21.08
Upgrade
Change in Working Capital
0.91-0.730.13-2.45-2.45
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.